Pharmacological and metabolic parameters of [ 18 F]flubrobenguane in clinical imaging populations.

Autor: Mair BA; Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada.; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada., Zelt JGE; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada.; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada., Nekesa K; Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada.; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada., Saint-Georges Z; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.; The University of Ottawa Institute of Mental Health Research at the Royal, Ottawa, Canada., Dinelle K; The University of Ottawa Institute of Mental Health Research at the Royal, Ottawa, Canada., Adi M; Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada.; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada., Robinson S; Lantheus Medical Imaging, Inc, North Billerica, MA, USA., Mielniczuk LM; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada., Shlik J; The University of Ottawa Institute of Mental Health Research at the Royal, Ottawa, Canada.; Department of Psychiatry, University of Ottawa, Ottawa, Canada., Beanlands RS; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada., deKemp RA; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. radekemp@ottawaheart.ca., Rotstein BH; Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada. benjamin.rotstein@uottawa.ca.; University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. benjamin.rotstein@uottawa.ca.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada. benjamin.rotstein@uottawa.ca.
Jazyk: angličtina
Zdroj: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology [J Nucl Cardiol] 2023 Oct; Vol. 30 (5), pp. 2089-2095. Date of Electronic Publication: 2023 Jul 26.
DOI: 10.1007/s12350-023-03338-9
Abstrakt: Background: Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[ 11 C]hydroxyephedrine, [ 18 F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.
Methods: Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.
Results: The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.
Conclusions: Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling.
(© 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.)
Databáze: MEDLINE
Externí odkaz: